Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520451 · ClinicalTrials.gov registry record · Phase 2
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
A Phase 2 study, sponsored by Principia Biopharma, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04520451 is a Phase 2 study that has completed, run by Principia Biopharma, a Sanofi Company. The registered enrollment target is 27 participants.
The verdict
NCT04520451, a Phase 2 study, has completed, sponsored by Principia Biopharma, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.
Interventions
- DRUG rilzabrutinib
- DRUG Glucocorticoids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-08-22 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04520451
The ClinicalTrials.gov registry entry for NCT04520451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Principia Biopharma, a Sanofi Company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rilzabrutinib is the first listed.
NCT04520451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04520451 about?
NCT04520451 is a clinical study titled "Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants". This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.
What is the current status of trial NCT04520451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-08-22. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT04520451?
The interventions under investigation include: rilzabrutinib (DRUG), Glucocorticoids (DRUG).
Who is sponsoring clinical trial NCT04520451?
This trial is sponsored by Principia Biopharma, a Sanofi Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.